title: Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
abstract: Therapeutic immunization of HIV-1-infected individuals with or without anti-retroviral therapy is a new promising disease prevention. To induce a new cytotoxic T(CD8) lymphocyte (CTL) immunity during chronic HIV-1 infection 15 infrequently targeted but conserved HLA-supertype binding CTL epitopes from Gag, Pol, Nef, Env, Vpu and Vif were identified. The 15 T(CD8) and three T(CD4) helper peptides were GMP synthesised and formulated with a new adjuvant CAF01 which is a synthetic two-component liposomic adjuvant comprising the quaternary ammonium dimethyl-dioctadecyl-ammonium (DDA) and the immune modulator trehalose 6,6'-dibehenate (TDB). Using IFN-γ ELISPOT assay, T-cell immune induction by the vaccine was found to both CD4 and CD8 T-cell restricted peptides in HLA-A2 transgenic mice. Comprehensive toxicity studies of the CAF01 adjuvant-alone and together with different vaccines showed that CAF01 when tested at human dose levels was safe and well tolerated with only local inflammation at the site of injection and no systemic reactions. No pharmacological safety issues were observed in Beagle dogs. The HIV-1 vaccine toxicity study in the Göttingen Minipig(®) showed no systemic toxicity from five repetitive i.m. injections, each with a 2-week interval, of either the 18 HIV-1 peptide antigen solution (AFO18) or the AFO18-CAF01, in which the 18 HIV-1 peptides were formulated with the CAF01 adjuvant. Distinct inflammatory responses were observed in the injected muscles of the AFO18-CAF01 vaccine treated animals as a result of the immune stimulating effect of the adjuvant on the vaccine. The results of the toxicity studies provide optimism for phase I clinical trials evaluating the therapeutic HIV-1 T-cell vaccination approach using multiple subdominant minimal epitope peptides applying the novel cationic adjuvant CAF01.
authors.affiliation: Virus Research & Development Laboratory, Department of Virology, Statens Serum Institut, Copenhagen, Denmark. afo@ssi.dk
authors.forename: Anders
authors.initials: A
authors.lastname: Fomsgaard
authors.forename: Ingrid
authors.initials: I
authors.lastname: Karlsson
authors.forename: Gregers
authors.initials: G
authors.lastname: Gram
authors.forename: Christian
authors.initials: C
authors.lastname: Schou
authors.forename: Sheila
authors.initials: S
authors.lastname: Tang
authors.forename: Peter
authors.initials: P
authors.lastname: Bang
authors.forename: Ingrid
authors.initials: I
authors.lastname: Kromann
authors.forename: Peter
authors.initials: P
authors.lastname: Andersen
authors.forename: Lars Vibe
authors.initials: LV
authors.lastname: Andreasen
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000494:pharmacology* / Q000633:toxicity; D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D058501:Enzyme-Linked Immunospot Assay / Q000379:methods; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005260:Female; D006017:Glycolipids / Q000009:adverse effects / Q000494:pharmacology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology; D007111:Immunity, Cellular / Q000276:immunology; D007114:Immunization / Q000379:methods; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects / Q000494:pharmacology; D013552:Swine; D013556:Swine, Miniature; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018675:Toxicity Tests / Q000379:methods
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D018984:Epitopes, T-Lymphocyte; D006017:Glycolipids; D015789:HLA-A2 Antigen; D010455:Peptides; D000644:Quaternary Ammonium Compounds; C507803:trehalose 6,6'-dibehenate; C015831:dimethyldioctadecylammonium